Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions-Reference-Cited by-同舟云学术

Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions

Published:2024-07-11 Issue:8 Volume:35 Page:1089-1115
ISSN:1043-1802
Container-title:Bioconjugate Chemistry
language:en
Short-container-title:Bioconjugate Chem.

Author:

Kamaraj Rajamanikkam¹^ORCID,Ghosh Subhrojyoti²^ORCID,Das Souvadra³,Sen Shinjini³,Kumar Priyanka³,Majumdar Madhurima³,Dasgupta Renesa³,Mukherjee Sampurna³,Das Shrimanti³,Ghose Indrilla³,Pavek Petr¹,Raja Karuppiah Muruga Poopathi⁴,Chuturgoon Anil A.⁵^ORCID,Anand Krishnan⁶^ORCID

Affiliation:

1. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Charles University in Prague, Heyrovskeho 1203, 50005 Hradec Kralove, Czech Republic

2. Department of Biotechnology, Indian Institute of Technology Madras, Chennai 600036, India

3. Department of Biotechnology, Heritage Institute of Technology, Kolkata 700107, India

4. Department of Chemistry, School of Physical Sciences, Central University of Kerala, Tejaswini Hills, Periye, Kasaragod District, Kerala 671320, India

5. Discipline of Medical Biochemistry, School of Laboratory Medicine and Medical Sciences, College of Health Sciences, Howard College Campus, University of KwaZulu-Natal, Durban 4041, South Africa

6. Department of Chemical Pathology, School of Pathology, Faculty of Health Sciences, University of the Free State, Bloemfontein, Free State 9300, South Africa

Funder

European Commission

Grantová Agentura, Univerzita Karlova

National Research Foundation

Universiteit van die Vrystaat

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.bioconjchem.4c00253

Reference212 articles.

1. The ion channel network in T lymphocytes, a target for immunotherapy

2. De-novo and acquired resistance to immune checkpoint targeting

3. Immunotherapies and Combination Strategies for Immuno-Oncology

4. Understanding the tumor microenvironment for effective immunotherapy

5. Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations